Clinical Cell Processing News – part 3, 2016

by Alexey Bersenev on July 2, 2016 · 1 comment

in clinical lab

Post to Twitter Send Gmail Post to LinkedIn

Clinical Cell Processing News is a series about new protocols, products and techniques for clinical-grade cell processing and manufacturing. Cell processing devices, cultureware, bioreactors, GMP-grade reagents, cell separation techniques. This series is posted every 2 months.

Protocol: PBMC isolation protocol using SynGenX-LAB System (SynGen)

Validation of CliniMACS Prodigy for clinical CAR T-cell manufacturing (Cytotherapy)

We found that transduction efficiencies, phenotype and function of CAR19 T cells were comparable with existing procedures and overall T-cell yields sufficient for anticipated therapeutic dosing. The automation of closed-system T-cell engineering should improve dissemination of emerging immunotherapies and greatly widen applicability.

1. Myeloid cells in PBMC concentrates inhibit the expansion of clinical CAR T-cells products (Cytotherapy)

Among the patients whose CD19-CAR T cells expanded poorly, manufacturing for two patients was repeated using cryopreserved PBMC concentrates but incorporating a monocyte depleting plastic adherence step, and an adequate dose of CAR T cells was produced for both patients.

2. Clinical-scale expansion of bone marrow-derived mesenchymal stromal cells for private banking (J Transl Med) FREE

68 clinical-grade large-scale MSC cultures were completed and analyzed. The whole process was described, including volunteer donor screening, bone marrow collection, mononuclear cell isolation and expansion over 4 weeks, harvesting, cryopreservation, release, administration and quality controls of the cells (including microbiology, phenotype, and potency assays).

3. Protocol: Validation of Quantum Cell Expansion System for clinical production of MSCs (Methods Mol Biol)

The chapter includes protocols for preparation of media, setup of the Quantum system, coating of the hollow fiber bioreactor, as well as loading, feeding, and harvesting of cells. We suggest a panel of quality controls for the starting material, the interim product, as well as the final product.

4. Protocol: Quality control assays for clinical-grade MSC (Methods Mol Biol)

This chapter describes analytical methods implemented and performed in our cell factory as part of the release strategy for an ATMP consisting of frozen autologous BM-derived MSC. Such methods are designed to assess the safety (sterility, endotoxin, and mycoplasma assays) and identity/potency (cell count and viability, immunophenotype and clonogenic assay) of the final product.

5. Validation of DSM BMC device for isolation of bone marrow MSCs (Cytotherapy)

MSCs were concentrated from bone marrow aspirate using the new device and the Ficoll method. The isolation capabilities of the device and the growth characteristics, secretome production, and differentiation capacity of the derived cells were determined.

6. Impact of cord blood banking technologies on clinical outcome – retrospective analysis (Transfusion) FREE

The primary aim of this study was to retrospectively analyze the impact of the major variables associated with CB banking on the clinical outcome of an extensive set of patients who have undergone a CBT. Data concerning 677 unrelated CBUs delivered for single CBT, carried out from 1997 to 2010 in centers affiliated to the European Society for Blood and Marrow Transplantation (EBMT; and reported to the Eurocord Registry, were collected from the banks that released the units.

7. Validation of cryopreservation of MSC expressing TRAIL (Cytotherapy) FREE

We tested different concentrations of dimethyl sulfoxide (DMSO) added to the human serum albumin ZENALB 4.5 and measured post-thaw cell viability, proliferation ability and differentiation characteristics. In addition, we examined the homing ability, TRAIL expression and cancer cell–killing capacities of cryopreserved genetically modified MSCs compared with fresh, continually cultured cells.

8. Clinical outcome after transplantation of HPC products with microbial contamination (Transfus Apher Sci)

The use of contaminated products with antibiotic prophylaxis may be safe in terms of the first day of fever, duration of fever, neutrophil, platelet engraftment and duration of hospitalization.

9. A single exercise enhances the manufacture of viral-specific T-cells from healthy donors (Sci Rep) FREE

We conclude that a single exercise bout enhances the manufacture of multi-VSTs from healthy donors without altering their phenotype or function and may serve as a simple and economical adjuvant to boost the production of multi-VSTs for allogeneic adoptive transfer immunotherapy.

10. Optimization of hematopoietic graft engineering: CD3/CD19 depletion or CD34 selection (Transfusion)

To optimize graft composition we compared 1) direct or indirect TCD only, 2) a combination of CD3/CD19-depleted with CD34-selected grafts, or 3) TCD twice for depletion improvement based on our 10-year experience with 320 separations in graft manufacturing and quality control.

New products and services:
Celluvative (Blood Center of Wisconsin and San Diego Blood Bank)
CliniCell – Clinical Grade Tissue (AllCells)
Beta: ThawSTAR – Thawing System for Cryobags (BioCision)

{ 1 comment… read it below or add one }

Simon Bogdansky July 9, 2016 at 9:46 am

I have read the promotional materials and product literature for Vivigen, manufactured by LifeNet Health and distributed by DePuy. It has cryopreserved stem cells but is claimed to be a 361 tissue product. Anyone know more? Is this another example of a self-launched stem cell product? Thanks.


Leave a Comment

Previous post:

Next post: